PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial ...
Updated data from VERSATILE-002 trial shows Versamune® HPV + pembrolizumab well-tolerated with mOS of 30 months, ORR of 36%, and DCR of 77% in HPV16-positive R/M HNSCC patients. 21% experienced 90-100% tumor shrinkage. Phase 3 trial VERSATILE-003 planned to start this year.
Reference News
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial ...
Updated data from VERSATILE-002 trial shows Versamune® HPV + pembrolizumab well-tolerated with mOS of 30 months, ORR of 36%, and DCR of 77% in HPV16-positive R/M HNSCC patients. 21% experienced 90-100% tumor shrinkage. Phase 3 trial VERSATILE-003 planned to start this year.